Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiuhua Fu

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)Hongyun Zhao, Wenxiu Yao, Xuhong Min, et al.
ERJ Open Research|August 18, 2025
C-BIOPRED severe asthma clinical phenotypes: link to complement and coagulation pathways and galectin 10Changxing Ou, Zhenan Deng, Yongkang Liao, et al.
Frontiers in Medicine|April 3, 2026
Heterogeneous impact of tea consumption on COPD risk in smokers: insights from the PIFCOPD studyYijing Li, Jiping Liao, Ruiying Wang, et al.
Respiratory Research|May 25, 2023
Ambient fine particulate matter and allergic symptoms in the middle-aged and elderly population: results from the PIFCOPD studyShanshan Wei, Jiping Liao, Tao Xue, et al.
Clinical and Translational Medicine|February 20, 2022
Severe eosinophilic asthma in Chinese C-BIOPRED asthma cohortQingling Zhang, Xiuhua Fu, Changzheng Wang, et al.
Clinical and Translational Allergy|September 30, 2022
Influence of sex, cigarette smoking and airway inflammation on treatable traits in CBIOPRED severe asthmaCong Dong, Xiaojing Yang, Wei Luo, et al.
Chinese Medical Journal|February 8, 2023
Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapiesZhenan Deng, Meiling Jin, Changxing Ou, et al.
International Journal of Antimicrobial Agents|June 8, 2024
A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patientsYing Li, Demei Zhu, Shenghua Sun, et al.
Eclinicalmedicine|November 29, 2021
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind studyRui Wan, Xiaorong Dong, Qun Chen, et al.
JAMA Oncology|November 14, 2024
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical TrialYing Cheng, Wei Zhang, Lin Wu, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)Hongyun Zhao, Wenxiu Yao, Xuhong Min, et al.
ERJ Open Research|August 18, 2025
C-BIOPRED severe asthma clinical phenotypes: link to complement and coagulation pathways and galectin 10Changxing Ou, Zhenan Deng, Yongkang Liao, et al.
Frontiers in Medicine|April 3, 2026
Heterogeneous impact of tea consumption on COPD risk in smokers: insights from the PIFCOPD studyYijing Li, Jiping Liao, Ruiying Wang, et al.
Respiratory Research|May 25, 2023
Ambient fine particulate matter and allergic symptoms in the middle-aged and elderly population: results from the PIFCOPD studyShanshan Wei, Jiping Liao, Tao Xue, et al.
Clinical and Translational Medicine|February 20, 2022
Severe eosinophilic asthma in Chinese C-BIOPRED asthma cohortQingling Zhang, Xiuhua Fu, Changzheng Wang, et al.
Clinical and Translational Allergy|September 30, 2022
Influence of sex, cigarette smoking and airway inflammation on treatable traits in CBIOPRED severe asthmaCong Dong, Xiaojing Yang, Wei Luo, et al.
Chinese Medical Journal|February 8, 2023
Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapiesZhenan Deng, Meiling Jin, Changxing Ou, et al.
International Journal of Antimicrobial Agents|June 8, 2024
A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patientsYing Li, Demei Zhu, Shenghua Sun, et al.
Eclinicalmedicine|November 29, 2021
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind studyRui Wan, Xiaorong Dong, Qun Chen, et al.
JAMA Oncology|November 14, 2024
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical TrialYing Cheng, Wei Zhang, Lin Wu, et al.
Pageof 4